StemCell Therapy

Management to Highlight Progress in Bone Marrow Transplant (BMT) and Chimeric Antigen Receptor T Cell (CAR T) Business Collaborations

Tel Aviv, Israel, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of cells facilitating safer and more efficacious cell and gene therapies, today announced that the leadership will be presenting at the Cell & Gene Meeting on the Mesa, which is being held from October 12th 16th. In addition to providing an overview of the Company, the management team will provide a progress update on the clinical and development programs and an overview of the Companys business strategy. Management will be virtually meeting cell and gene therapy companies to support collaborations.

This is one of the most prestigious meetings for our industry, and despite it being virtual this year due to the COVID-19 pandemic, it will not dampen our enthusiasm commented Dr. Yarkoni. We have successfully adjusted our operations, and we continue to make significant progress with our Israel and U.S.-based clinical trials. We are also taking meaningful steps to accelerate nearer-term revenue opportunities as we are collaborating with several partners that are looking to leverage our technology platform to help improve their products, especially in high-growth areas such as CAR T, NK (natural killers) and MSCs. We are looking forward to sharing the progress we have made and also look forward to meeting with current and potential partners developing cell and gene therapies.

To schedule a meeting with the Companys Chief Executive Officer, Dr. Shai Yarkoni or Chief Operating Officer, Amos Ofer, please request a meeting through the meeting portal and/or contact the Company direct at shai@cellect.co or amoso@cellect.co. The presentation will be available on the Companys website prior to the commencement of the meeting. The Cell & Gene Meeting on the Mesa is the sectors foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures.

About Cellect Biotechnology Ltd.

Cellect Biotechnology (APOP) has developed a breakthrough technology, for the functional selection of cells that aims to improve the robustness, safety and efficacy of a variety of cell and gene therapies. The Companys technology can be used by researchers, clinical community and pharma companies in a wide variety of applications including next generation Car T, NK, MSC and gene therapies.

The Company is also developing its own product that is an improved BMT which is in a current clinical trial for cancer treatment.

Forward Looking Statements

This press release contains forward-looking statements about the Companys expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as believe, expect, intend, plan, may, should, could, might, seek, target, will, project, forecast, continue or anticipate or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in this press release when we discuss Cellects expectations regarding timing of the commencement of its planned U.S. clinical trial and its plan to reduce operating costs. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the Companys history of losses and needs for additional capital to fund its operations and its inability to obtain additional capital on acceptable terms, or at all; the Companys ability to continue as a going concern; uncertainties of cash flows and inability to meet working capital needs; the Companys ability to obtain regulatory approvals; the Companys ability to obtain favorable pre-clinical and clinical trial results; the Companys technology may not be validated and its methods may not be accepted by the scientific community; difficulties enrolling patients in the Companys clinical trials; the ability to timely source adequate supply of FasL; risks resulting from unforeseen side effects; the Companys ability to establish and maintain strategic partnerships and other corporate collaborations; the scope of protection the Company is able to establish and maintain for intellectual property rights and its ability to operate its business without infringing the intellectual property rights of others; competitive companies, technologies and the Companys industry; unforeseen scientific difficulties may develop with the Companys technology; the Companys ability to retain or attract key employees whose knowledge is essential to the development of its products; and the Companys ability to pursue any strategic transaction or that any transaction, if pursued, will be completed. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading Risk Factors in Cellect Biotechnology Ltd.s Annual Report on Form 20-F for the fiscal year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SECs website, http://www.sec.gov, and in the Companys periodic filings with the SEC.

ContactCellect Biotechnology Ltd.Eyal Leibovitz, Chief Financial Officerwww.cellect.co+972-9-974-1444

Or

EVC Group LLCMichael Polyviou(732) 933-2754mpolyviou@evcgroup.com

Read this article:
Cellect Biotechnology to Present at the 2020 Cell & Gene Meeting on the Mesa - GlobeNewswire

Cell and Gene Therapy Market Research Report is a Proficient and In-Depth Study on the Existing State of Cell and Gene Therapy Industry. This Report Focuses on the Major Drivers, Restraints, Opportunities and Threats for Key Players. It also Provides Granular Analysis of Market Share, Segmentation, Revenue Forecasts and Regional Analysis till 2025.

The recent study on Cell and Gene Therapy market offers an all-inclusive analysis of this vertical, with emphasis on the growth driving factors as well as facets such as consumption and production. Constraints and potential threats expected to restrain the expansion along with solutions to overcome the challenges are discussed at length. Moreover, insights of the market share along with estimates reflecting the CAGRs of the listed segments are highlighted in the document.

In hindsight of the COVID-19 pandemic, the report investigates the prevalent business strategies employed by leading organizations and offers tactics for stakeholders to adapt to the industry changes over the forecast period.

Request Sample Copy of this Report @ https://www.aeresearch.net/request-sample/307400

Key pointers from the Cell and Gene Therapy market report TOC:

Additional highlights from the Cell and Gene Therapy market report:

Reasons to buy the report

Request Customization on This Report @ https://www.aeresearch.net/request-for-customization/307400

Read the original post:
Cell and Gene Therapy Market Report 2020 Industry Capacity, Manufactur - News by aeresearch

T-knife GmbH, a next-gen adoptive T-cell company, and Catalent, have signed an agreement to provide technology transfer and CGMP clinical manufacturing of T-knifes T1367 T-cell receptor (TCR) program.

T1367 is an autologous T-cell receptor-based cell therapy derived from T-knifes proprietary humanized T-cell receptor (HuTCR) mouse platform and specifically targets MAGE-A1 positive tumors in cancer patients. The therapy is expected to be manufactured for clinical trials in both the EU and U.S.

Catalent will undertake transfer of T-knifes platform process for T-cell receptor-based cell therapy at its site in Gosselies, Belgium, with the goal of manufacturing clinical batches for European trials in 2021. T-knife will also prepare for the transfer of the TCR manufacturing platform to Catalents Houston, TX, facility for clinical trials in North America in the future.

The product candidates based on our proprietary HuTCR platform require sophisticated, state-of-the-art manufacturing capabilities and deep cell and gene therapy know-how, said Michael Buchholz, Director Manufacturing of T-knife. We are convinced that Catalent is the right partner for T-knife to ensure premier manufacturing of our pipeline programs, covering all stages from clinical trials to market.

Catalent is well-suited to support T-knife with focused technology transfer and process industrialization in both Gosselies and Houston, commented Manja Boerman, Ph.D., President, Cell & Gene Therapy, Catalent. Emerging and innovative treatments like T1367 are moving rapidly to the clinic. Catalent is committed to continual investment and expansion to support our clients as they continue on the journey to commercialization.

Catalents 25,830 sq.-ft. facility in Gosselies, Belgium, provides clinical through commercial-scale cell therapy manufacturing, for both autologous and allogeneic cell therapy treatments. An additional large-scale commercial manufacturing plant is currently under construction at the site and expected to be fully commissioned in 2021. The companys clinical manufacturing site in Houston is under qualification and expected to be fully commissioned in 2020.

Original post:
T-knife, Catalent Sign Tech Transfer And Mfg. Pact For Cell Therapy - Contract Pharma

DUARTE, Calif.--(BUSINESS WIRE)--City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, today announced that it has licensed intellectual property relating to its pioneering chlorotoxin chimeric antigen receptor (CLTX-CAR) T cell therapy to Chimeric Therapeutics Limited, an Australian biotechnology company.

The therapy is currently being used in a phase 1 clinical trial at City of Hope to treat glioblastoma (GBM), a type of brain tumor. The first patient in the trial was recently dosed; Behnam Badie, M.D., chief of City of Hopes Division of Neurosurgery and The Heritage Provider Network Professor in Gene Therapy, is leading this innovative, first-of-its-kind trial.

Chimeric has acquired the exclusive worldwide rights to develop and commercialize certain patents relating to City of Hopes CLTX-CAR T cells, as well as to further develop the therapy for other cancers.

City of Hope is excited to enter into this agreement with Chimeric as it supports our innovative research in CAR T cell therapy and our commitment to extend these therapies to more patients, particularly those with GBM and other solid tumors that are difficult to treat, said Christine Brown, Ph.D., The Heritage Provider Network Professor in Immunotherapy and deputy director of City of Hopes T Cell Therapeutics Research Laboratory. Chimeric shares our goal of providing effective CAR T cell therapies to more patients with current unmet medical needs.

Led by Brown and Michael Barish, Ph.D., chair of City of Hopes Department of Developmental and Stem Cell Biology, and Dongrui Wang, Ph.D., a recent graduate of City of Hopes Irell & Manella Graduate School of Biological Sciences, the team developed and tested the first CAR T cell therapy using CLTX, a component of scorpion venom, to direct T cells to target brain tumor cells. The research was published this past March in Science Translational Medicine.

Chimeric is excited to join City of Hope in its quest to find more effective cancer therapies. This is an exceedingly rare opportunity to acquire a promising technology in one of the most exciting areas of immuno-oncology today, said Paul Hopper, executive chairman of Chimeric. Furthermore, the CLTX-CAR T cell therapy has completed years of preclinical research and development, and recently enrolled its first patient in a phase 1 clinical trial for brain cancer.

CARs commonly incorporate a monoclonal antibody sequence in their targeting domain, enabling CAR T cells to recognize antigens and kill tumor cells. In contrast, the CLTX-CAR uses a synthetic 36-amino acid peptide sequence first isolated from death stalker scorpion venom and now engineered to serve as the CAR recognition domain.

In this recent study, City of Hope researchers used tumor cells in resection samples from a cohort of patients with GBM to compare CLTX binding with expression of antigens currently under investigation as CAR T cell targets. They found that CLTX bound to a greater proportion of patient tumors, and cells within these tumors.

CLTX binding included the GBM stem-like cells thought to seed tumor recurrence. Consistent with these observations, CLTX-CAR T cells recognized and killed broad populations of GBM cells while ignoring nontumor cells in the brain and other organs. The study team demonstrated that CLTX-directed CAR T cells are highly effective at selectively killing human GBM cells without off-tumor targeting and toxicity in cell-based assays and in animal models.

City of Hope, a recognized leader in CAR T cell therapies for GBM and other cancers, has treated more than 500 patients since its CAR T program started in the late 1990s. The institution continues to have one of the most comprehensive CAR T cell clinical research programs in the world it currently has 30 ongoing CAR T cell clinical trials, including CAR T cell trials for HER-2 positive breast cancer that has spread to the brain, and PSCA-positive bone metastatic prostate cancer. It was the first and only cancer center to treat GBM patients with CAR T cells targeting IL13R2, and the first to administer CAR T cell therapy locally in the brain, either by direct injection at the tumor site, through intraventricular infusion into the cerebrospinal fluid, or both. In late 2019, City of Hope opened a first-in-human clinical trial for patients with recurrent GBM, combining IL13R2-CAR T cells with checkpoint inhibitors nivolumab, an anti-PD1 antibody, and ipilimumab, blocking the CTLA-4 protein.

Both an academic medical center and a drug development powerhouse, City of Hope is known for creating the technology used in the development of human synthetic insulin and numerous breakthrough cancer drugs. Its unique research and development hybrid of the academic and commercial creates an infrastructure that enables City of Hope researchers to submit an average of 50 investigational new drug applications to the U.S. Food and Drug Administration each year. The institution currently holds more than 450 patent families.

"City of Hope is delighted to license this technology to Chimeric, said Sangeeta Bardhan Cook, Ph.D., City of Hope director of the Office of Technology Licensing. We are impressed with the ability of their executive team to push and bring therapies to market expeditiously. At City of Hope, our mission is to transform the future of health care. We believe Chimeric has the vision to offer innovative therapies to cancer patients.

About City of Hope

City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases. Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy. City of Hopes translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin and numerous breakthrough cancer drugs are based on technology developed at the institution. A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope has been ranked among the nations Best Hospitals in cancer by U.S. News & World Report for 14 consecutive years. Its main campus is located near Los Angeles, with additional locations throughout Southern California. For more information about City of Hope, follow us on Facebook, Twitter, YouTube or Instagram.

View original post here:
City of Hope Enters Licensing Agreement With Chimeric to Develop Its Pioneering Chlorotoxin CAR T Cell Therapy - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. (Genprex or the Company) (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced it has named Thomas C. Gallagher, Esq. as the Companys Senior Vice President of Intellectual Property and Licensing. Mr. Gallagher has extensive experience in the area of biotechnology intellectual property (IP) law, business development, and licensing transactions with industry and academic institutions.

Mr. Gallagher will play a critical role in advancing our expanding intellectual property estate by spearheading IP strategy, which is an important element of the Companys overall success and value creation. A seasoned biotech executive, he will provide significant support as we execute on broadening our research and development programs, explore opportunities for partnerships on our existing programs, and opportunistically acquire new technologies to further expand our pipeline, said Rodney Varner, President and Chief Executive Officer of Genprex.

Mr. Gallagher has more than 20 years of experience as an intellectual property attorney. Prior to joining Genprex, he served as Principal at the Fenagh Group, an IP and licensing consultancy providing clients in the healthcare sector guidance on all aspects of patent and trademark portfolio management, intellectual property due diligence, freedom-to-operate analysis and related transactional work. He has also served as Senior Vice President of Intellectual Property and Licensing at Kadmon Corporation, LLC, a biopharmaceutical company based in Manhattan. Prior to joining Kadmon, he served as in-house IP counsel at Neostem Inc. (now Caladrius Biosciences, Inc.), a company focused on stem cell biology. Previously, he held several positions at ImClone Systems Incorporated, most recently as Vice President of Intellectual Property and Licensing. While at ImClone, he was responsible for all aspects of intellectual property and led the IP function in multiple due diligence undertakings by major pharmaceutical companies, which resulted in a $2 billion strategic investment, the highest-valued biotech deal ever at the time, and the eventual sale of the company to Eli Lilly and Company for $6.5 billion.

Mr. Gallagher is experienced in both patent prosecution and litigation, as well as intellectual property issues relating to business development and licensing matters. His patent litigation experience includes European litigation and opposition proceedings. In addition to a law degree, Mr. Gallagher holds a Masters degree in molecular biology. Before becoming an attorney, Mr. Gallagher worked as a molecular biologist in France, Spain and the United States.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprexs technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Companys lead product candidate, GPX-001 (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. GPX-001 has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZenecas Tagrisso) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the Companys web site at http://www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of Genprexs product candidates, alone and in combination with other therapies, on cancer and diabetes, regarding potential, current and planned clinical trials, regarding the Companys future growth and financial status and regarding our commercial partnerships and intellectual property licenses. Risks that contribute to the uncertain nature of the forward-looking statements include the presence and level of the effect of our product candidates, alone and in combination with other therapies, on cancer; the timing and success of our clinical trials and planned clinical trials of GPX-001, alone and in combination with targeted therapies and/or immunotherapies, and whether our other potential product candidates, including GPX-002, our gene therapy in diabetes, advance into clinical trials; the success of our strategic partnerships, including those relating to manufacturing of our product candidates; the timing and success at all of obtaining FDA approval of GPX-001 and our other potential product candidates including whether we receive fast track or similar regulatory designations; costs associated with developing our product candidates, whether we identify and succeed in acquiring other technologies and whether patents will ever be issued under patent applications that are the subject of our license agreements or otherwise. These and other risks and uncertainties are described more fully under the caption Risk Factors and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

See the original post:
Genprex Names Seasoned IP Executive, Thomas C. Gallagher, as Senior Vice President of Intellectual Property and Licensing - Business Wire

PARIS--(BUSINESS WIRE)--Regulatory News:

GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported that statistical analysis of pooled data from LUMEVOQ trials and natural history studies found a statistically significant and clinically meaningful difference between the visual outcomes in LUMEVOQ-treated patients and untreated patients.

Treated eyes showed progressive and sustained improvement from Month 12 to Month 52, in contrast to the absence of recovery over the same period for untreated eyes. At Month 18, the difference became statistically significant (p=0.01). By Month 48, the difference between the mean visual acuity in treated patients and that in untreated patients was both statistically significant (p<0.01) and clinically meaningful (-0.33 LogMAR, or +16.5 ETDRS letters equivalent, in favor of treated eyes).

Note: All patients had a confirmed G11778A mutation in the ND4 mitochondrial gene and were at least 15 years old. The diagram shows the Locally Estimated Scatterplot Smoothing (LOESS) curves for visual acuity in LUMEVOQ-treated patients and untreated patients. The shaded areas represent the 95% confidence interval for the mean BCVA. Treated eyes refer to all eyes (LUMEVOQ and sham) from the RESCUE, REVERSE and CLIN06 trials (N=76 patients / 152 eyes). Untreated eyes refer to patient-level data from the REALITY study and a matched data set from two prospective and eight retrospective natural history studies1 (N=208 patients / 408 eyes). LOESS curves were estimated using a non-parametric, local regression model that treated each eye as independent of the other. LOESS curves are shown from Month 12 to depict post-treatment progression among treated patients (93% of LUMEVOQ patients had already been treated within 12 months from onset). *Statistically significant difference between mean visual acuity of treated and untreated eyes at M18, M24, M36 and M48, as illustrated by the non-overlapping confidence intervals.

The analysis compared data from the completed Phase III trials RESCUE and REVERSE studies and interim results from the long-term follow-up CLIN06 study to a matched sample created from the REALITY registry study and 10 other natural history studies1. The natural history studies were identified from an extensive review of the scientific literature and selected based on specific inclusion criteria for their patient-level data. In all, the visual outcomes in 76 treated patients could be compared to the visual outcomes of 208 untreated patients.

The extra granularity of this analysis down to individual patient data confirms that the natural history of visual outcomes in ND4-LHON patients is poor and provides the best comparison we have for assessing the therapeutic efficacy of gene therapy, commented Dr. Nancy J. Newman, MD, LeoDelle Jolley Professor of Ophthalmology and Neurology at the Emory University School of Medicine in Atlanta, GA, USA, and a global authority on LHON who recently completed a meta-analysis of the natural history of ND4-LHON.2

Separate analyses of patients enrolled in RESCUE and REVERSE demonstrated similarly favorable results compared to untreated patients. Full findings from the indirect comparison were included in the European Marketing Authorisation Application (MAA) for LUMEVOQ and are being prepared for publication in a peer-reviewed journal.

This indirect comparison represents a significant contribution to our understanding of LUMEVOQs therapeutic effect," said Dr. Jos-Alain Sahel, MD, Director of the Institut de la Vision (Sorbonne-Universit/Inserm/CNRS), Paris, France; Chairman of the Department of Ophthalmology at Centre Hospitalier National dOphtalmologie des XV-XX, Paris, France; Professor and Chairman of the Department of Ophthalmology at University of Pittsburgh School of Medicine and UPMC (University of Pittsburgh Medical Center), USA; and Co-Founder of GenSight Biologics. The use of a large external control group, including analyses of patient-level data, provides more evidence for a significant treatment-related visual improvement.

The findings are a gratifying outcome of our push to overcome a key challenge for assessing LUMEVOQs efficacy, namely the inability of sham eyes to act as a control group, commented Bernard Gilly, Co-founder and Chief Executive Officer of GenSight. We are excited to take this evidence that LUMEVOQ modifies the disease outcome forward into our conversations with national and regional authorities.

The LUMEVOQ MAA was filed in September, and the decision is expected in H2 2021. The Company is also working towards submitting LUMEVOQs Biologics License Application (BLA) to the FDA in H2 2021.

GenSight will host a conference call today, September 21, 2020, at 10am CEST in French, and at 2.00pm CEST (8.00am EST) in English, to discuss these results.

Webcast & Conference call in French (10am CEST)

Dial-in numbers:

United States: +1 212 999 6659France: +33 (0)1 7037 7166United Kingdom: +44 (0)20 3003 2666Password: GenSight FR

Webcast link: https://bit.ly/3mAS0Vy

Webcast & Conference call in English (2.00pm CEST / 8.00am EST)

Dial-in numbers:

United States: +1 212 999 6659France: +33 (0) 1 7037 7166United Kingdom: +44 (0) 20 3003 2666Password: GenSight ENG

Webcast link: https://bit.ly/35RCfnl

A replay of the calls and webcasts will be available by using the above links.

Rationale for the Indirect Comparison

In both the REVERSE and RESCUE studies, as well as in the long-term follow-up study CLIN06, unilaterally injected patients experienced an unexpected visual improvement in their contralateral eye, which mirrored the sustained and clinically relevant gain in eyes treated with LUMEVOQ. This bilateral improvement eliminated the control group that was to consist of sham eyes in the original trial design. An indirect comparison methodology, based on formal statistical methods applied to an external control group, was needed to assess the magnitude of LUMEVOQ efficacy.

Methodology Highlights

The sample of LUMEVOQ-treated patients included all data from the two pivotal studies REVERSE and RESCUE and Year 3 data from the ongoing extension study CLIN06. This approach yielded a treated patient pool consisting of 76 patients (152 eyes), with LUMEVOQ-injected eyes and sham-treated eyes considered equivalent, based on the contralateral effect demonstrated in the studies.

The external control group included data from the REALITY Natural History registry and patient-level data from 10 published articles1 on ND4-LHON, which were identified from a systematic review of the literature. ND4-LHON studies were included in the indirect comparison only if they had individual patient data that would allow indirect comparison with LUMEVOQ-treated patients: confirmed ND4 genotype, at least 15 years of age, at least one BCVA measurement with associated time of vision loss. The final external control group included 208 patients (408 eyes).

The visual acuity curves of treated and untreated patients were defined using a Locally Estimated Scatterplot Smoothing (LOESS), non-parametric, local regression model. They were aligned in terms of time from vision loss for the statistical tests performed at M12, M18, M24, M36 and M48 from vision loss and at the last available observation. The starting time point for the statistical tests (12 months post-vision loss) was defined to enable assessment of LUMEVOQ efficacy, as 93% of LUMEVOQ patients were treated by that time.

1The 10 studies that passed the inclusion criteria were: Hotta 1995, Lam 2014, Nakamura 1993, Newman 1991, Qu 2007, Qu 2009, Romero 2014, Sadun 2004, Yang 2016, and Zhou 2010.

2Newman NJ, Carelli V, Taiel M and Yu-Wai Man P. Visual outcomes in Leber hereditary optic neuropathy patients with the m.11778G>A (MTDN4) mitochondrial DNA mutation. J Neuro-Ophthalmol. In Press. 2020.

About GenSight Biologics

GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics lead product candidate, LUMEVOQ (GS010; lenadogene nolparvovec), has been submitted for marketing approval in Europe for the treatment of Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease affecting primarily teens and young adults that leads to irreversible blindness. Using its gene therapy-based approach, GenSight Biologics product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.

About LUMEVOQ (GS010)

LUMEVOQ (GS010) targets Leber Hereditary Optic Neuropathy (LHON) by leveraging a mitochondrial targeting sequence (MTS) proprietary technology platform, arising from research conducted at the Institut de la Vision in Paris, which, when associated with the gene of interest, allows the platform to specifically address defects inside the mitochondria using an AAV vector (Adeno-Associated Virus). The gene of interest is transferred into the cell to be expressed and produces the functional protein, which will then be shuttled to the mitochondria through specific nucleotidic sequences in order to restore the missing or deficient mitochondrial function. LUMEVOQ was accepted as the invented name for GS010 (lenadogene nolparvovec) by the European Medicines Agency (EMA) in October 2018.

About Leber Hereditary Optic Neuropathy (LHON)

Leber Hereditary Optic Neuropathy (LHON) is a rare maternally inherited mitochondrial genetic disease, characterized by the degeneration of retinal ganglion cells that results in brutal and irreversible vision loss that can lead to legal blindness, and mainly affects adolescents and young adults. LHON is associated with painless, sudden loss of central vision in the 1st eye, with the 2nd eye sequentially impaired. It is a symmetric disease with poor functional visual recovery. 97% of patients have bilateral involvement at less than one year of onset of vision loss, and in 25% of cases, vision loss occurs in both eyes simultaneously. The estimated incidence of LHON is approximately 1,400 to 1,500 new patients who lose their sight every year in the United States and Europe.

About RESCUE and REVERSE

RESCUE and REVERSE are two separate randomized, double-masked, sham-controlled Phase III trials designed to evaluate the efficacy of a single intravitreal injection of GS010 (rAAV2/2-ND4) in subjects affected by LHON due to the G11778A mutation in the mitochondrial ND4 gene.

The primary endpoint measures the difference in efficacy of GS010 in treated eyes compared to sham-treated eyes based on BestCorrected Visual Acuity (BCVA), as measured with the ETDRS at 48 weeks post-injection. The patients LogMAR (Logarithm of the Minimal Angle of Resolution) scores, which are derived from the number of letters patients read on the ETDRS chart, will be used for statistical purposes. Both trials have been adequately powered to evaluate a clinically relevant difference of at least 15 ETDRS letters between treated and untreated eyes adjusted to baseline.

The secondary endpoints involve the application of the primary analysis to bestseeing eyes that received GS010 compared to those receiving sham, and to worseseeing eyes that received GS010 compared to those that received sham. Additionally, a categorical evaluation with a responder analysis was evaluated, including the proportion of patients who maintain vision (< ETDRS 15L loss), the proportion of patients who gain 15 ETDRS letters from baseline and the proportion of patients with Snellen acuity of >20/200. Complementary vision metrics include automated visual fields, optical coherence tomography, and color and contrast sensitivity, in addition to quality of life scales, biodissemination and the time course of immune response. Readouts for these endpoints are at 48, 72 and 96 weeks after injection.

The trials were conducted in parallel, in 37 subjects for REVERSE and 39 subjects for RESCUE, in 7 centers across the United States, the UK, France, Germany and Italy. Week 96 results were reported in 2019 for both trials, after which patients were transferred to a long-term follow-up study that will last for three years.

ClinicalTrials.gov Identifiers:REVERSE: NCT02652780RESCUE: NCT02652767

About CLIN06 (RESCUE and REVERSE Long-term Follow-up)

CLIN06 is the long-term follow-up study of ND4 LHON subjects treated with LUMEVOQ (GS010) gene therapy in the RESCUE or REVERSE Phase III Clinical Trials. The total study period for an individual subject is 3 years, i.e., 5 years post-gene therapy administration. No study treatment is administered during CLIN06.

The primary objective is to assess the long-term safety of intravitreal LUMEVOQ administration up to 5 years post-treatment. The secondary objective is to assess the long-term treatment efficacy of the therapy and the quality of life (QoL) in subjects up to 5 years post-treatment. The first subject was enrolled on January 9, 2018. 61 subjects have enrolled.

ClinicalTrials.gov Identifiers:CLIN06: NCT03406104

About REALITY

REALITY is a multi-country retrospective and cross-sectional observational study of affected LHON subjects, based on subjects medical charts and the administration of surveys on Health-Related Quality of Life (HRQoL) and direct and indirect costs associated with the disease.

The study aimed to recruit at least 50 subjects (both adult and pediatric) chiefly in the following countries: Spain, Italy, France, United Kingdom and the United States.

The primary objectives for the REALITY study were: to describe the evolution of visual functional and structural changes and other associated symptoms in patients with LHON; understand the impact of LHON-related vision loss on the HRQoL; and understand the economic burden for patients and their families arising from direct and indirect costs associated with the disease. The secondary objective is to describe the relationship between genetic, lifestyle and/or environmental factors and the expression of the LHON phenotype.

The first subject was enrolled on 3 January 2018. Enrollment was completed in early Q2 2020.

ClinicalTrials.gov Identifiers:REALITY LHON Registry: NCT03295071

See original here:
GenSight Biologics Reports New Analysis Demonstrating Statistically Significant and Clinically Meaningful Difference Between Visual Outcomes in...

The Global Urology Implants And Devices Market is projected to grow considerably on account of increasing incidence of urology disorders. Key insights into this development have been provided by Fortune Business Insights in its report, titled Urology Implants and Devices Market Size, Share and Global Trend By Product Type (Endoscopes, Lithotripsy Devices, Urodynamic Systems, Urostomy Bag, Endo Vision Systems & Peripheral Instruments, Urology Implants), By Disease (Kidney Disorders, Urology Cancers, Urinary Tract Disorders, Pelvic Organ Prolapse), By End User (Hospitals, Pharmacies, Ambulatory Surgery Centers (ASC)) and Geography Forecast till 2026.

The report covers:

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/urology-implants-and-devices-market-100434

Leading Players operating in the Urology Implants and Devices Market are:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

Segmentation

By Products

By Disease

By End-Users

By Region

More Trending Topics From Fortune Business [emailprotected]

Gene Therapy Market

Gene Therapy Market

Gene Therapy Market

Gene Therapy Market

Gene Therapy Market

Gene Therapy Market

Gene Therapy Market

Gene Therapy Market

Gene Therapy Market

Gene Therapy Market

Gene Therapy Market

Gene Therapy Market

Gene Therapy Market

Gene Therapy Market

Gene Therapy Market

Gene Therapy Market

Gene Therapy Market

Gene Therapy Market

Gene Therapy Market

Gene Therapy Market

Read more here:
Urology Implants and Devices Market Size 2020 Top Manufacturers, Share, Opportunities and Forecast to 2026 - The Daily Chronicle

Viral Vector and Vaccine Market report is an excellent report that makes it possible to the Viral Vector and Vaccine industry can be highly benefited with this market research report which brings market and competitive landscape clearly into the focus and help make better decisions. Market segmentation has also been performed in detail based on various parameters that include applications, verticals, deployment model, end user, and geography. Expert solutions combined with potential capabilities prepare this winning Viral Vector and Vaccine Market document to be outperforming for the Viral Vector and Vaccine

Get Sample PDF (including COVID19 Impact Analysis) of Viral Vector and Vaccine Market Report@https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-viral-vector-and-vaccine-market

Viral vector & vaccine market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to growing with the CAGR of 14.50% in the above mentioned forecast period. Rising prevalence of contagious and chronic diseases such astuberculosis, HIV, and cancer has given a boost to market for finding effective solution for these problems whereas upcoming new disease like with outbreak of COVID-19 has raised demand for minimal invasive technique for treatment for these rising medical problems.

The Leading Market Players Covered in this Report are :

Regional Analysis Includes:

Asia-Pacific-China, Japan, Korea, India, and Southeast Asia

Europe-Germany, France, UK, Russia, and Italy etc.

North America-The United States, Mexico, and Canada

South America-Brazil, Argentina, Columbia, etc.

The Middle East and Africa-Saudi Arabia, UAE, Egypt, Nigeria, and South Africa

Deep analysis about market status, enterprise competition pattern, advantages and disadvantages of enterprise products, industry development trends, regional industrial layout characteristics and macroeconomic policies, industrial policy has also be included.

Viral vector & vaccine market is segmented on the basis of type, workflow, application and end use. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Viral vector & vaccine market is segmented on the basis of type, workflow, application and end use. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

From raw materials to downstream buyers of this industry will be analyzed scientifically, the feature of product circulation and sales channel will be presented as well. In a word, this report will help you to establish a panorama of industrial development and characteristics of the Viral Vector and Vaccine Market.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert@ https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-viral-vector-and-vaccine-market

Recent Developments

o Market Overview and growth analysiso Import and Export Overviewo Volume Analysiso Current Market Trends and Future Outlooko Market Opportunistic and Attractive Investment Segment

Key Questions Answered by Viral Vector and Vaccine Market Report

1. What was the Viral Vector and Vaccine Market size in 2018 and 2019?; what are the estimated growth trends and market forecast?2. What will be the CAGR of Viral Vector and Vaccine Market during the forecast period (2020 2027)?3. Which segments (product type/applications/end-user) were most attractive for investments in 2018?How these segments are expected to grow during the forecast period (2020 2027).4. Which manufacturer/vendor/players in the Viral Vector and Vaccine Market was the market leader in 2018?5. Overview on the existing product portfolio, products in the pipeline, and strategic initiatives taken by key vendors in the market.

There are 13 Chapters to thoroughly display the Viral Vector and Vaccine Market. This report included the analysis of market overview, market characteristics, industry chain, competition landscape, historical and future data by types, applications and regions.

Chapter 1: Viral Vector and Vaccine Overview, Product Overview, Market Segmentation, Market Overview of Regions, Market Dynamics, Limitations, Opportunities and Industry News and Policies.

Chapter 2: Viral Vector and Vaccine Industry Chain Analysis, Upstream Raw Material Suppliers, Major Players, Production Process Analysis, Cost Analysis, Market Channels and Major Downstream Buyers.

Chapter 3: Value Analysis, Production, Growth Rate and Price Analysis by Type of Viral Vector and Vaccine.

Chapter 4: Downstream Characteristics, Consumption and Market Share by Application of Viral Vector and Vaccine.

Chapter 5: Production Volume, Price, Gross Margin, and Revenue ($) of Viral Vector and Vaccine by Regions (2020 2027).

Chapter 6: Viral Vector and Vaccine Production, Consumption, Export and Import by Regions (2020 2027).

Chapter 7: Viral Vector and Vaccine Market Status and SWOT Analysis by Regions.

Chapter 8: Competitive Landscape, Product Introduction, Company Profiles, Market Distribution Status by Players of Viral Vector and Vaccine.

Chapter 9: Viral Vector and Vaccine Market Analysis and Forecast by Type and Application (2020 2027).

Chapter 10: Market Analysis and Forecast by Regions (2020 2027).

Chapter 11:Industry Characteristics, Key Factors, New Entrants SWOT Analysis, Investment Feasibility Analysis.

Chapter 12:Market Conclusion of the Whole Report.

Chapter 13:Appendix Such as Methodology and Data Resources of This Research.

Find More Competitor in TOC with Profile Overview Share Growth Analysis @https://www.databridgemarketresearch.com/toc/?dbmr=global-viral-vector-and-vaccine-market

Customization of the Report:

Data Bridge Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Thanks for reading this article; you can also get individual chapter wise section or region wise report versions like North America, Europe, or Asia Etc.

About Us:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to complex business challenges and initiates an effortless decision-making process.

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

ccorporatesales@databridgemarketresearch.com

GLOBAL CONGRESS ON ELDERLY CARE, GERONTOLOGY AND GERIATRICS

The world is ageing rapidly. People aged 60 and older make up 12.3 per cent of the global population, and by 2050, that number will rise to almost 22 per cent. With this surge many issues are underlying related to blood pressure, diabetes, heart failure issues, arthritis, cancer malignancy, joint pains, tuberculosis and majorly the lack of awareness regarding the changing behavioural patterns in elderly people at home leading to abuse of them by their kin.

The goal of this Conference is uniting all well-known gerontologists, geriatrics scholars, policy decision-makers, professional activists, related companies, and researchers to discuss and share knowledge in the emerging field of Aging and Gerontology and its related areas of research and how we can move towards more Healthy Living, Healthy Aging to Promote an Ageless Era and hence widening professional contact and create new opportunities, including establishing new collaborations to all the representatives.Registration Link: https://bit.ly/34ueelz

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.

View post:
Viral Vector and Vaccine Market To 2027 Reporting And Evaluation Of Recent Industry Developments | - PharmiWeb.com

Written by Hena SharmaAllyssia Alleyne, CNN

Today, many of us are buying new clothes too often, and not holding on to what we already own for long enough. In 2017, the Environmental Protection Agency reported that 11.2 million tons of textile waste in the US ended up in landfills. Across the pond, in the UK, the average lifespan for a garment is just over two years, according to a 2017 report from the Waste and Resources Action Programme.

So before throwing out a garment at the first sign of wear, consider how you can extend your wardrobe's lifespan. Here are a few tips.

Quick fixing

Visible mending

"Visible mending" refers to the process of repairing holes and signs of wear on clothes in bold, obvious ways. In Japan, such flaws are embraced through the handiwork of Japanese Sashiko (literally "little stabs"), a practice that uses hand embroidery to create a delicate pattern over tears in jeans, sweaters or dresses.

Stain removal

Stains may not mark the end of the road for a piece of clothing. If you spilled your tea or coffee, soak the garment in water and vinegar. Have a makeup stain? Apply shaving cream to the area, let it sit for 10 minutes and rinse with cold water, then repeat the process with hot water.

Upcycling and repurposing

Sometimes a garment can't be saved in its current form, but it can have a second life in your closet. If you've got sewing prowess and are up for a challenge, you can try upcycling pieces at home, creating something new from used clothes.

Read this article:
How to increase the longevity of your wardrobe - CNN

If youre like me during the COVID-19 pandemic, your TV viewing habits have consisted of two guilty pleasures: reality TV and, of late, the return of live sports.

Terry Bradshaw is synonymous with live sporting events, as hes helped set up NFC matchups on FOXs NFL coverage since 1994. A Pro Football Hall of Famer, four-time Super Bowl-winning quarterback and broadcast icon, Bradshaw is adding reality TV star to his resume with his new show, The Bradshaw Bunch, premiering on hayu Canada on Friday, Sept. 18.

I caught up with Bradshaw ahead of the premier of his new show, which will release new episodes for stream or download every Friday, in anticipation of the Week 2 NFL schedule to find out what hes looking for, what players he loves to watch and how playing in his era compares to playing now.

Sportsnet: Did you ever think youd be doing a reality show?

Terry Bradshaw: Well, actually, this is my second reality show.

I did a show with NBC called Better Late Than Never, which is about a bunch of old actors and football players and boxers George Foreman, Henry Winkler, William Shatner and a young comedian named Jeff Dye. We travel around the country, and we did that show for two years and then thought we were going back out. NBC pulled the plug on it. And that was it. So, I have done one before this one.

This show was brought to me by Jason Ehrlich, who was executive producer of Better Late Than Never. He had come to a birthday party and he had seen my three girls and how they interacted with me and how much fun we had together. Light bulb went off.

I said, OK, lets do this. Away we went.

SN: Weve all consumed more TV during the pandemic. What are you watching? What reality shows do you watch?

TB: Duck Dynasty was pretty much it. Thats the only reality show I watch. Im not a reality guy. Im an old movies guy. I like to watch old movies. My wife, she likes to watch old movies. We love documentaries and we love sporting events. So glad they are back.

SN: On your NFL show on FOX, youve got a couple of co-hosts who have done some reality shows themselves. Have they weighed in?

TB: Howie thinks its going to be a hit. Jimmy thinks the same thing. He thinks its going to be funny. Michael Strahan was kind of surprised that I would do something like this, but he thinks it will be good.

All of them are very, very encouraging. Theyre very polite because theyre really good friends. Now, the show airs Friday, though. By Sunday, when I get there Sunday, they may go, T.B., what were you doing? They might be getting ready to rib me waiting for me in my parking spot on Sunday. But otherwise, everybodys asking, Whens the show? Whens it going to be on?

And its about my family. They know my family. They know my grandkids. So, you know, theyre very supportive right now.

SN: The reality show that you help bring to us as viewers is the NFL. Looking at the star character of the league, Patrick Mahomes and his big arm, you have something in common with him: when you played you were known for your arm talent. How do you evaluate the way guys like Mahomes can spin it now?

TB: I think Mahomes has got a good arm. He doesnt have a howitzer, but he can throw it. Hes very good in traffic. Great peripheral vision, throws it from all angles, very accurate, good under pressure, quick release. Tremendous talent.

Weve got other guys. The guy who played against him in Week 1, Deshaun Watson. He can really spin it and probably spin it a little better than Patrick. Hes not Patrick Mahomes, but is awfully good. Weve got Ben Roethlisberger who can really throw.

But the face of our league is, youre right, Patrick Mahomes from Kansas City. That is just a special talent and fun to watch any time. Hes one of the few players that I know, hes on television, Im watching that. Of course, my wife is a Kansas City Chiefs fan, so I have to be careful when Im on the air. Stay off of our boy, she says, because he sent her a signed helmet. And so, you know what that means. He bought my mouth.

SN: But I mean, the Pittsburgh Steelers helped you buy your house. So how does that work?

TB: Exactly.

Well, she knows for a fact that if it went between Pittsburgh and Kansas City, youre history. Thats where you draw the line. Lets not get crazy here. I mean, I spent 14 years at this organization. We won a lot of Super Bowls.

SN: If you had to build the perfect QB from the guys playing right now you could Frankenstein it up how would you build it?

TB: I would start with the strength of Roethlisberger.

I would follow that up with Tom Brady. I mean, theres so many guys that have the clutch gene. He is very much clutch. Hes great in the fourth quarter. Hes great in overtime. Its just amazing. I probably take Bradys calmness under pressure.

Ill take Drew Brees for accuracy. Escape ability, athleticism and the wow factor is Mahomes.

Three out of the four quarterbacks have strong arms. Probably fans would have no idea the strongest arm of all of them Brady believe it or not has a very strong arm.

Ive got a pretty good answer. You take those four players; I got a pretty good quarterback. Yeah, you win some games there.

SN: Youre in your 70s. Youve got so much energy, but you mentioned Tom. Hes 43 now and still playing. Can you imagine that?

TB: Yes, I can imagine playing nowadays at that age as much as I love playing. Had I not gotten hurt, my goal was to play and last to 40. I missed that target as I was 33.

But I missed it by seven years. So, I cant imagine. But I also understand it. Why not? Listen to what a young man does. A kid does. He dreams of playing in the NFL. Its his passion. And he gets there, and the dream comes true. And then its, I want to win championships and that comes true. And theres just nothing greater in life. Experiencing your dream unfold in front of you. And you have tremendous success at what you envision is the greatest job in the world, playing quarterback in the National Football League.

So, yeah, I certainly can get it. Why would you want to retire when youre doing what you want to do? You love what you want to do. You have a good team around you. So, youre competitive and youre making tons of money. Why give that up? So, I dont blame him whatsoever. I got hurt. And once it was over, you cant go back. Im proud of what hes doing and all of what hes doing. There is not many guys willing to do what he is doing this, you know, vegetable ice cream and stuff like that.

God bless him for that. Sounds like horrible, horrible ice cream. If Im eating ice cream, Im eating real, peach ice cream. Thats the real deal.

SN: Absolutely (laughs). Is todays game easier for quarterbacks now than when you played?

TB: Yeah, absolutely.

Professional football in Canada or in the National Football League, to play the position of quarterback, its not easy to handle the pressure, block everything from your mind, separate coverages, deliver the ball without realizing that people are hanging all over you.

Ive got one of the greatest pictures, most exciting pictures I have of myself: just all you see are people and at the very top of my hand with the football coming out of my hand and you can hardly see me.

That is the coolest picture I have ever seen. I just love that it shows me that Im oblivious to whats around me. And thats what you have to have to play quarterback.

It is easier to play in the sense that when I played in the 70s, you could get hit, you could get body slammed. You didnt have a suspension helmet, early part of my career, no chinstraps. I mean, the rules were changed back in the late 70s. It slowly started changing to where you couldnt jab or jam a receiver at the line of scrimmage up to five yards. Get your hands off of it as opposed to bump-and-run all over the football field.

So, its a totally different game. The game you see today in the NFL is the old AFL of the 60s. Thats why Ive often said 40, 50 times passing is the reason they did it because passing the football is exciting. And the NFL of the first 70 years from the first day, up to about 78, was just hard run, run, run, play action, run, run. Boring.

And the merger of the AFL and NFL was predominantly because the AFL was gaining. They were garnering ratings, taking them away from CBS, and it was because their brand of football was exciting. It was really fun to watch.

And what youre seeing today is the 60s of the AFL, especially in the last year. Its so much fun to watch.

Read the original here:
Q&A: Terry Bradshaw on the perfect QB, Bradys longevity and reality TV - Sportsnet.ca

In a study published in the US National Library of Medicine National Institutes of Health, the effect of ginger on the lipid levels was investigated.

The study noted, 45 patients in the treatment group and 40 patients in the placebo group participated in this study".

There was a significant reduction in triglyceride, cholesterol, low-density lipoprotein (LDL), very low-density lipoprotein, levels of before and after study separately in each group," it continued.

Mean changes in triglyceride and cholesterol levels of the ginger group were significantly higher than the placebo group.

Mean reduction in LDL level and increase in high density lipoprotein level of ginger group were higher than the placebo group, but in VLDL level of placebo was higher than ginger."

READ MORE:Best supplements for the heart - the 2p capsules to protect against heart disease

Read the original here:
How to live longer: A spice known to help curb cancer growth and boost longevity - Express

While there are few studies demonstrating the exact benefits of drinking celery juice, a lot of research points to how celery and its seeds can promote healthy living.

A study published in 2013 investigated whether the chemical 3-n-butylphthalide (3nB) in celery seed extract has antihypertensive properties.

Thirty participants with high blood pressure took part, and each consumed a capsule containing 75 milligrams of celery seed extract, twice a day for six weeks.

After this time, the participants experienced a significant decrease in blood pressure.

READ MORE:Prostate cancer symptoms: The one sign of the deadly disease all men should look out for

High blood pressure can lead to serious problems such as heart attacks and strokes.

But according to the researchers, 3nB may lower blood pressure by reducing the buildup of fatty deposits within the arteries and increasing the elasticity of artery walls.

Celery may also benefit a persons cholesterol levels.

High cholesterol is when a person has too much of a fatty substance called cholesterol in their blood.

DON'T MISS

Too much cholesterol can block the blood vessels and make a person more likely to have heart problems or a stroke.

But a 2014 study investigated the effects of celery leaf extract on the cholesterol levels of rats fed a high-fat diet.

The rats were fed celery leaf extract for 30 days, after which they showed a significant decrease in low-density lipoprotein (LDL) or bad cholesterol when compared to rats that didnt receive the extract.

Celery contains some beneficial antioxidants, one being luteolin.

The researchers found rats that were continuously treated with luteolin had reduced brain cell damage and improved learning and memory.

A different review published in 2015 looked at the effect of different plant chemicals on rodents with Alzheimers disease.

Researchers found apigenin, another antioxidant found in celery, limits damage to a variety of brain processes.

This could delay and slow the progression of Alzheimers disease.

Follow this link:
How to live longer: The juice that could ward off high blood pressure and boost longevity - Express

SAN FRANCISCO, Sept. 16, 2020 /PRNewswire/ -- A leading authority and author on aging partners with an award-winning tech journalist for the new monthly podcast, What's Next: Living Longer, Better, Smarter launching today. The hosts, Mary Furlong, a successful entrepreneur in the $8.3 trillion longevity economy, and former CBS, Bloomberg and public radio reporter, Fred Fishkin, will offer fresh perspectives into the worlds of technology and aging by interviewing notable thought leaders on a variety of topics focused on adults age 50+.

"We are delighted to be partnering with technology media expert Fred Fishkin to highlight trends in the longevity market," said Mary Furlong, the executive producer of the What's Next Longevity conferences which offer a platform for entrepreneurs to build sustainable brands. "Fred and I worked together 20 years ago through our CBS partnership and are pleased to be leveraging our knowledge base and distribution to bring a fresh set of perspectives around healthy aging using technology."

"Mary is a leading voice and advocate for seniors, longevityand I have to say it living longer, better and smarter!" said Fred Fishkin, who is re-teaming with Furlong after having worked with her at Third Age in the late 90s. "It is an opportunity to bring the depth of her knowledge to the growing number of people who have been turning to podcasts for news and entertainment. And the guests we will have on and the topics we have plannedcovering the intersection of technology, longevity and agingwill be very exciting."

The podcast topics will include: changes in Medicare for telemedicine since COViD-19, the impact on older voters in the 2020 election, the innovative tech solutions to address social isolation in seniors and a holiday gadget gift guide for the age 50+ crowd. The first podcast is a tribute to the late author (Passages) and aging icon, Gail Sheehy, who passed away on August 24 at age 83. Mary Furlong (Turning Silver Into Gold) shares her memories of her friend along with authors and friends of Gail, Ciji Ware (Landing by Moonlight, Rightsizing Your Life) and Sherri Snelling (A Cast of Caregivers). What's Next: Living Longer, Stronger, Better podcast will be available on: Anchor, Pocket Casts, Radio Public, Spotify, Spreaker, PodcastAddict, PodChaser. Google Play, iTunes and iHeartRadio and many other podcasting outlets..

According to a report from Infinite Dial 20, 55% of the U.S. population roughly 155 million people has listened to a podcast. Among those, listeners age 55+ make-up 20% of the entire podcast audience. According to Nielsen, podcast listeners are more likely to follow companies and brands on social media they hear about on podcasts and 69% agreed that podcast ads made them aware of new products or services.

About Mary Furlong Mary is the President and CEO of Mary Furlong & Associates, and is a leading authority on the longevity marketplace. She is an author, educator, and serial entrepreneur, and she has helped to guide the business and marketing strategies of leading corporations, emerging companies and nonprofits. Interested sponsors can learn more at: maryfurlong.com

About Fred Fishkin Fred is an award-winning journalist who has worked with CBS Radio, Bloomberg and NPR, and has hosted a long-running daily radio and online report on consumer technology. He also works with Princeton University and the faculty chair of autonomous vehicle engineering on a regular podcast focused on using technology to provide mobility for all. Find more of Fred's work at http://www.techstination.com and http://www.smartdrivingcar.com.

Media Contact: Mary Furlong - (925) 323-0312, 247587@email4pr.com Fred Fishkin Fishkin@techstination.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/new-podcast-presents-power-player-interviews-at-intersection-of-longevity-and-technology-301132098.html

SOURCE Mary Furlong Associates

Go here to read the rest:
New Podcast Presents Power Player Interviews at Intersection of Longevity and Technology - Stockhouse

The link between the foods we eat and the length of our life expectancy is firmly established. Eating healthily can bolster your defences against a host of chronic diseases, not least heart disease - a major killer worldwide. Extensive research has extolled the virtues of healthy eating.

Health bodies routinely advocate eating a diet that is full of fruits and vegetables, whole grains, nuts, fish, poultry, and vegetable oils.

For good reason too. In a study published in The Journal of nutrition, people with diets consistent with a healthy dietary pattern had a 31 percent lower risk of heart disease, a 33 percent lower risk of diabetes, and a 20 percent lower risk of stroke.

Much emphasis is placed on the foods we eat but less is understood about the frequency of our eating habits.

Speaking to the Express.co.uk, Dr Sarah Brewer, Medical Director of Healthspan and Author of Live Longer, Look Younger, shed some light on the current research in this area.

READ MORE:How to live longer: Consume this spice to reduce heart disease risk and inhibit cancer

"Restricting your calorie intake can significantly extend your lifespan, although you may argue that life quality is reduced," she said.

Unfortunately, as Dr Brewer explained, you need to restrict calorie intake to 60-70 percent of your normal daily needs to prolong your lifespan by 30-50 percent.

This can be a tall order, especially if you have a mentally and demanding lifestyle.

However, eating every other day (i.e. fasting one day, and eating what you like the next) appears to produce similar effects with health benefits starting within as little as two weeks, noted Dr Brewer.

DON'T MISSCoronavirus symptoms: The main difference youd feel if you have COVID-19, cold or flu[INSIGHT]Hair loss treatment: The herbal oil proven to promote hair growth and improve dandruff[TIPS]Best supplements: Pill known to help lower blood sugar and reduce health risks[ADVICE]

This insight comes from researchers writing in the journal Medical Hypotheses.

As Brewer reported, the researchers suggested this strategy might improve insulin resistance, asthma, allergies, infections, autoimmune diseases (eg asthma, rheumatoid arthritis), osteoarthritis, heart problems and menopausal symptoms.

It may also delay, prevent or improve neurological conditions such as Alzheimer's, Parkinson's and multiple sclerosis.

Rethinking your eating habits should not come at the cost of regular exercise, however.

"Exercise can partially reverse the effects of the ageing process on physiological functions and preserve functional reserve in the elderly," said Dr Brewer.

Numerous studies have shown that maintaining a minimum quantity and quality of exercise decreases the risk of death, prevents the development of certain cancers, lowers the risk of osteoporosis and increases longevity.

One notable study involving more than 10,000 men found that exercise reduced the number of age-related deaths from all causes by almost a quarter - even if exercise was not started until middle age, reported Dr Brewer.

"In particular, deaths from coronary heart disease were reduced by 41 percent and risk of stroke reduced by 50 percent," she said.

Regular exercise has also been shown to prevent diabetes, with the protective effect appearing strongest in those with the highest risk, said Dr Brewer.

"Both the Finnish Diabetes Prevention Study and the Diabetes Prevention Program found that changes in lifestyle of high-risk overweight subjects with impaired glucose tolerance reduced the risk of type 2 diabetes by 58 percent," she reported.

Furthermore, exercise appears to reduce the risk of certain cancers, especially those of the colon, rectum and uterus, she added.

According to the NHS, adults should do at least 150 minutes (two hours and 30 minutes) of moderate-intensity aerobic activity, such as cycling or fast walking, every week.

Read the rest here:
How to live longer: How often you should eat to extend your life expectancy - Express

Date published: September 19 2020

Guenther Steiner says that, in deciding who will drive for Haas next season, he and the team are thinking beyond 2021.

The American team currently has two seats free for next year, with neither Romain Grosjean nor Kevin Magnussen being offered new deals as of yet.

With Sergio Perez and Nico Hulkenberg available, as well as a number of younger drivers, there are a number of options for the team. As many as 10, Steiner recently claimed.

There are close to 10 [options], he told Autosport.

It is amazing what is around at the moment. Thats why you see me very calm. Because there are only 20 seats, and we have got 10 potential people which could do the job, which is good.

Two of them we have got already.

Get your hands on the official Haas 2020 collection via the Formula 1 store

In the eyes of many, Perez and Hulkenberg are the two best options, with both having proved themselves to be excellent midfield drivers on the grid.

However, while they may be the best for next season, with new regulations on the horizon, Steiner is thinking ahead to beyond then.

I dont want to go through all the criteria but it needs to be a package, and we need to see what do we want to do in the future, he said.

Were not just thinking about next year. Then, if youre short on thinking, it is pretty easy: you try to get the fastest guy as quickly as possible in.

But we are thinking about the next five years after we have signed our Concorde Agreement now. So, we want to build up again, that we are getting back to the results that we had in 2018.

That takes a bit more time to think it through: financially, talent, its a lot of things coming into play. And that is where we are. As I said, we are in no hurry.

In terms of younger drivers, the team has both Pietro Fittipaldi and Louis Deletraz in its ranks. Whats more, due to the close relationship with Ferrari, Mick Schumacher and Robert Shwartzman are genuine possibilities.

Follow us on Twitter@Planet_F1and like ourFacebook page.

Visit link:
Guenther Steiner favouring longevity in driver selection | PlanetF1 - PlanetF1

Certain non-obvious daily habits can interfere with longevity and increase your risk of cancer. Oncologist Robert Thomas, who teaches in Cambridge, warned about this, reports the Daily Mail.

Image via: pixabay.com If the toast is burnt during preparation, the doctor advises against eating it. Under the influence of high temperatures in foods containing starch and sugar, acrylamide compounds are formed, which are considered toxic. They threaten DNA damage and put a significant strain on the immune system, increasing the risk of cancer. Although one burnt toast will not harm your health, it is worth considering if such a dish is constantly included in the diet.

Fresh blackberries are good anti-carcinogenic agents. However, a berry bought in a store does not have such pronounced properties, it can also contain pesticides and toxins.

Vegetable chips are not the best substitute for potato chips, the oncologist warned, since they are about as harmful. Such healthy snacks are often made from beets and carrots, where the sugar is even higher and the level of acrylamides is higher, which threatens cancer.

For cheese lovers, it is better to choose blue, it contains a lot of bacteria that are beneficial to the body. Also, the product has a positive effect on the work of the digestive tract.

See the original post:
Burnt toast and vegetable chips: Oncologist named subtle habits that increase the risk of cancer and interfere with longevity - The Times Hub

Sept. 20, 1883: John Appleton (1804-1891) of Bangor, chief justice of the Maine Supreme Judicial Court, retires after serving 20 years and 11 months in that role, longer than any other chief justice in Maine history.

A New Hampshire native, the Bowdoin College graduate was admitted to the bar in that state, then moved back to Maine to practice law in Dixmont, Sebec and Bangor. He was appointed as a Maine Supreme Judicial Court associate justice in 1852, then became chief justice in 1862.

Appleton influenced the development of Maine law greatly. His treatise The Rules of Evidence, Stated and Discussed, published in 1860, set a template on that subject that became a national model. He was also noted for his embrace of free-market capitalism and opposition to government loans or tax breaks for businesses.

In December 2019, Chief Justice Leigh Saufley completes her 18th year as chief justice, a time in that office second only to that of Appleton. She announces in April 2020 that she will step down later in the year to become dean of the University of Maine School of Law. As a result, Appletons longevity record remains intact.

Sept. 20, 1993: Victoria Vicky Van Meter (1982-2008) of Meadville, Pennsylvania, who began flying airplanes at age 10, becomes at age 11 the youngest girl ever to fly across the United States from east to west when she flies a Cessna 172 from Augusta to San Diego, California, taking five days to make the trip. Her record is later broken.

The following year, at age 12, Van Meter becomes the youngest female pilot to make a trans-Atlantic flight when she files a Cessna 210 from Augusta to Glasgow, Scotland.

Van Meter later graduates from Edinboro University in Pennsylvania with a bachelors degree in criminal justice, then becomes a Peace Corps worker in Moldova, a former part of the Soviet Union. In 2008, having battled depression and resisted taking medication, she dies from a self-inflicted gunshot wound.

A statue of her in the Augusta State Airports terminal building commemorates her 1993 transcontinental achievement.

Joseph Owen is an author, retired newspaper editor and board member of the Kennebec Historical Society. Owens book, This Day in Maine, can be ordered at islandportpress.com. To get a signed copy use promo code signedbyjoe at checkout. Joe can be contacted at: [emailprotected]

Invalid username/password.

Please check your email to confirm and complete your registration.

Use the form below to reset your password. When you've submitted your account email, we will send an email with a reset code.

Previous

See the rest here:
On this date in Maine history: Sept. 20 - Press Herald

Advertisers arent looking for vanilla placements anymore. What they seek is a higher engagement, top-of-the-mind recall value and the consistent reach through one medium.

Call for entries open for BuzzInContent Awards 2020 ENTER NOW

Theres hardly any property on TV other than Bigg Boss on Colors that offers this valuable assortment to brands. According to industry experts, despite being the costliest property on Indian television, brands get as high as 3X to 5X ROI in terms of media value on Bigg Boss.

Top media planners said what Bigg Boss offers isnt just high viewership because of high entertainment value, but also seamless content integration and longevity as it runs for more than three months and over 100 episodes. The upcoming season starts on October 3.

Longevity wins the race

Soumit Deb

Media experts suggest what makes Bigg Boss an attractive proposition is its longevity and entertainment value. Bigg Boss is one of the biggest properties in the Hindi Entertainment space for more than a decade now. What makes it big is obviously the celebrity anchor and the longevity of the show with 100 plus episodes. All brands associated with Bigg Boss are the ones that realise that the longevity will help them grow their viewership and increase the recall value, says Soumit Deb, General Manager, MediaCom.

What we could figure from the third-party data is that the presenting sponsor always gets 3x media value. I believe thats why most of them come back, otherwise, why anyone would come back year after year, he added.

Mahesh Shetty

Mahesh Shetty, Head, Network Sales, Viacom18, says when advertisers see that the money they have invested got 5x returns in terms of media value, it becomes a lucrative buy. He said brands like Vivo, Lays and Dabur benefited a lot last year.

Seamless content Integration

A large part of this success has to be attributed to how seamlessly integration is done without compromising with the content. Shetty said, they work on brand briefs and then have to balance the brands demand along with the viewers. Theres a lot of to and fro and we have a team as a part of the sales team which conceptualises ideas as different brands have different needs and focuses on delivering the value to the partnered brands. It is a fine balance, our objective is to deliver value to both the viewer and the advertiser and there are times when the brands come up with good ideas, he said.

Citing an example, he said Vivo wanted to amplify their phones video-recording facility, so we got one of the housemates Shefali Bagga, who happens to be a news anchor, to record edgy interviews with some of the housemates, which were recorded on the Vivo phone and the features of the phone were amplified over there. At the same time, great content was created. The ideal mix is when you make great content and at the same time amplify brand properties.

Kishan Kumar MS

Kishan Kumar MS, Chief Growth Officer and South, Head, Wavemaker India, said, Snapdeal has used Bigg Boss beautifully to leverage the offline and online audiences. It depends on how well you leverage the platform. We have seen that FMCG brands that have stories to tell with synergies to the show have benefitted. Nippon Paint was the first brand to completely redesign the Bigg Boss house for Tamil and that worked well for us, he added.

Rising number of brand associations

In the last few years, there have been some memorable brand integrations on the show. Such associations include the Vodafone caller of the week, and Appy Fizz Zone, Garnier Mens Face Wash, Clean and Dry and Maruti Suzuki Swift.

Mohit Joshi

Mohit Joshi, MD, India, Havas Media Group, says, Bigg Boss is a strong platform and has grown well over the years. The number of brand associations has increased and rightfully so. In the 2006 first season, we had extensively used Reckitt Benckiser products in the show. The integration was seamless and was very well appreciated. Over the years I have seen many more integrations happening. We had also integrated the Hyundai Eon in Big Boss' task once.

This season, Mobile Premier League is the Presenting Sponsor of the reality series and Dabur Dant Rakshak Ayurvedic Paste and Tresemme are the Powered by Sponsors.

According to Deb, the brands that are ready to invest would benefit the most with Bigg Boss. From a sponsor point of view, a lot many things happen in the house. It is not only about placements but many other things happen inside the house like a branded task. So each brand picks up elements from the house. This helps the brands recall and amplifies it. So the winner here clearly is the one who invests that kind of money on the show.

With so many sponsors up for grabs, when we asked Shetty whether there are any criteria for selecting these sponsors, he said, It depends on the category, for example, HUL is our partner. They have a plethora of brands but they associate just one. It depends on who closed the deal first for that category and at the best possible price. At times there are also categories that make a lot of sense from a content point of view for us and for those we take a call accordingly.

Info@BestMediaInfo.com

See the original post:
Why brands turn to Bigg Boss despite being arguably the costliest property - Best Media Info

Autoplay

Show Thumbnails

Show Captions

EAST RUTHERFORD If things had worked out the way they were supposed to for the New York Jets, Frank Gore wouldnt have started a single game for them this season.

But a hamstring injury to LeVeon Bell in the season-opener changed things. And when the Jets host the San Francisco 49ers on Sunday at MetLife Stadium, theyll be relying on Gore to carry most of the running load against one of the best defenses in the NFL. And the 37-year-old expects to deliver.

I always prepared like I was the guy, just because you never know what happens in this league, said Gore, who is in his 16th NFL season. Thats why I go out every day on the practice field and prepare like I do. If my number gets called, I want to be ready.

It feels almost fitting that Gore will get this opportunity against his former team, the 49ers.

Gore has found a place among the greatest running backs in NFL history with a combination of durability and relentlessness. It all started with the 49ers in 2005, where he spent the first 10 years of his career.

Gore still has love for the 49ers. His profile picture on Twitter is a red and gold No. 74, with the 49ers logo on it, honoring the retirement of Joe Staley, the offensive tackle who spent so many years blocking for Gore.

Gore said this weekend that he plans to retire with the 49ers if he ever does decide to retire.

New York Jets running back Frank Gore (21) looks on prior to the game against the Buffalo Bills at Bills Stadium.[RICH BARNES/USA TODAY SPORTS](Photo: Rich Barnes, Rich Barnes-USA TODAY Sports)

But when he takes the field at MetLife Stadium, Gore will put all those feelings to the side and do everything in his power to beat his former team.

I want to win, Gore said. Especially with us coming off a loss last week. I want us to look a lot better than last week, as an offense, as a team. And thats doing whatever it takes to win. It could be the 49ers, Seattle, whatever. I just want to get a win.

The 49ers will surely be doing all they can to make it a difficult day for Gore, too. But what Gore was able to accomplish with the 49ers he had his best seasons in San Francisco, including all five of his Pro Bowl selections still lingers more than six years after he last played for the organization.

"I love Frank Gore, 49ers coach Kyle Shanahan told reporters as he prepared to play the Jets. I think he's one of the best running backs to ever play. I think he's one of the more underrated running backs to ever play. His longevity and his numbers now have finally given him a little bit more attention that is past due.

Gore passed Barry Sanders last fall, becoming the third-leading rusher in NFL history. He trails only Walter Payton and Emmitt Smith. Shanahan never coached him in San Francisco. But as a young quality control coach for the Buccaneers, Shanahan remembers watching Gores film from the University of Miami, and what he saw in 2004 left an impression even before Gore started marching toward history.

FILE - In this Dec. 18, 2005, file photo, San Francisco 49ers running back Frank Gore, left, is tackled by Jacksonville Jaguars defender Mike Peterson, right, during the second quarter of an NFL football game in Jacksonville, Fla. Gore took his first NFL snaps as a pro with the 49ers in 2005 in what seems like a lifetime ago for the NFL's third-leading rusher. It all comes full circle for the 37-year-old Gore on Sunday, Sept. 20, 2020, when his New York Jets host the team with which he began his career 16 years ago. (AP Photo/Phil Coale, File)(Photo: The Associated Press)

My first year in the league I remember watching his [film] in Tampa, just coming out of Miami just studying him, Shanahan said. I loved him then, I loved him every year. He runs so hard. The guys that run that hard very rarely can play to his age, which just shows how dedicated he is, how much of a football player he is and obviously extremely talented, but he's a special dude."

Relentlessness is one of the things that makes Gore special. Hes never liked sitting out preseason games. And at age 37, hes not particularly thrilled with the weekly maintenance plan that has him sitting out every Thursday practice as a rest day.

Jets coach Adam Gase has been a vocal supporter of Gore since he had the chance to coach him with the Dolphins in 2018. And while hell be mindful of Gores carries on Sunday, hell also knows that keeping his workload down will be easier said than done.

I have an idea, Gase said. But last time I had an idea, it just went a little sideways and we [the Dolphins] were playing Chicago, next thing I know he looked like he lost about 15 pounds in that game. I try to be smart as far as managing his carries and his reps, trying to get those other guys involved and then at the same time, you know, Frank likes to get in a rhythm so he wont like standing over there too long.

Gore had 15 carries for 101 yards for the Dolphins against the Bears that day, his 44th career game with 100 or more yards. He had his 45th and most recent 100-plus-yard last year with te Bills, going for 109 yards on 17 carries. If the Jets hope to beat the 49ers, it would help a lot of Gore could eclipse 100 yards for the 46th time in his career.

The Jets announced Saturdaythat they have signed linebacker Alec Ogletree from the practice squad to the active roster for Sunday's game. They also elevated two players to the active roster: running back Josh Adams and wide receiver Josh Malone.

Ogletree has started all 93 games he's appeared in during a seven-year NFL career, including 13 last year with the Giants. He was added to the Jets' practice squad in earlier this month and wasn't on the roster for the season-opener in Buffalo. It's unclear what role he'll play with the Jets, but he could start.

Avery Williamson ramped up his practice this week, but it's unclear if he'll be able to play after missing Week 1 with a hamstring injury. Ogletree and Neville Hewitt are the only healthy inside linebackers on the roster.

Adams and Malone have now both been elevated from the practice squad to the active roster for the second time, and will be able to return to the practice squad without passing through waivers -- one ofthe rule changes for playing this season during the pandemic.

But if the Jets want either on the active roster for a third time later this season, they won't be able to elevate them: they'll have to sign them to a player contract and they'll have to pass through waivers to return to the practice squad.

Andy Vasquezis the Jetsbeat writer for NorthJersey.com. For unlimited access to all Jets analysis, news, trades and more, pleasesubscribe todayanddownload our app.

Email:vasqueza@northjersey.comTwitter:@andy_vasquez

Read the original post:
NY Jets' Frank Gore, 37, gets a chance to prove he's still got it on Sunday vs. 49ers - NorthJersey.com

STEAMBOAT SPRINGS The Howelsen tunnel along the Yampa River Core that connects Yampa Street with Howelsen Hill will be closed from Monday, Sept. 21, to Thursday, Sept. 24, for scheduled maintenance.

The tunnel was built of concrete culvert sections, and the joint sealing the sections together no longer holds water. Contractors will inject an epexoy resin into the joints to reseal the area and prevent water from seeping into the tunnel.

Signs will help reroute Core Trail users to Yampa Street between Fifth and 10th streets.

Readers around Steamboat and Routt County make the Steamboat Pilot & Todays work possible. Your financial contribution supports our efforts to deliver quality, locally relevant journalism.

Now more than ever, your support is critical to help us keep our community informed about the evolving coronavirus pandemic and the impact it is having locally. Every contribution, however large or small, will make a difference.

Each donation will be used exclusively for the development and creation of increased news coverage.

Visit link:
Yampa River Core Trail tunnel near Howelsen closed until Friday - Steamboat Pilot and Today